Intrexon appoints Geno Germano president

Monday, May 23, 2016

Intrexon, a provider of synthetic biology, has appointed Geno Germano to the new role of president of Intrexon effective June 1, reporting to Chairman and Chief Executive Officer Randal J. Kirk. As president, Germano will help lead Intrexon’s management team and commercialization efforts utilizing the company’s technology platform for biologically-based solutions across a broad range of industries. Each of Intrexon’s five sectors and the office of the chief operating officer will report to Germano. 

[Read More]

Ziopharm-Intrexon collaborate with Merck Serono

Wednesday, April 1, 2015

Ziopharm Oncology, a Boston, Mass.-based biotech company, and Intrexon, a synthetic biology provider, have announced their oncology programs will be strengthened through Intrexon’s new global collaboration focused exclusively on novel chimeric antigen receptor T-cell (CAR-T) products with Merck Serono, the biopharmaceutical division of Merck. Intrexon will share the economic provisions of this collaboration, including upfront payment, milestones and royalties, equally with Ziopharm.

[Read More]

Intrexon completes acquisition of MediStem

Monday, March 10, 2014

Intrexon, a provider of synthetic biology, has completed the acquisition of San Diego-based Medistem, a pioneer in the development of Endometrial Regenerative Cells (ERCs), universal donor adult-derived stem cells with properties uniquely suited for therapeutic use with Intrexon’s existing suite of synthetic biology technologies.

[Read More]

Synthetic Biologics raises $10.8M financing

Tuesday, October 30, 2012

Synthetic Biologics, an Ann Arbor, Mich.-based biotech that develops of synthetic biologics and innovative medicines for serious diseases and unmet medical needs, has entered into definitive stock purchase agreements with accredited investors to raise approximately $10.8 million in a private placement financing.

[Read More]

Synthetic Biologics, Intrexon collaborate on infectious diseases

Wednesday, August 8, 2012

Synthetic Biologics, an Ann Arbor, Mich.-based developer of synthetic biologics and innovative medicines for unmet medical needs, and Intrexon, a Germantown, Md.-based synthetic biology company that provides control over cellular function, have entered into a second worldwide exclusive channel collaboration through which Synthetic Biologics intends to develop and commercialize a series of monoclonal antibody (mAb) therapies for the treatment of certain infectious diseases not adequately addressed by existing therapies.

[Read More]